tiprankstipranks
Analyst Profile
Followed by 32 other investors
.
Gobind Singh

Gobind Singh

JMP Securities
Wall Street Analyst
Ranked #7,974 out of 8,047 Analysts on TipRanks (#21,133 out of 21,521 overall experts)

Success Rate

0%
0 out of 25 Profitable Transactions

Average Return

-64.60%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
If you copied Gobind Singh's ratings since 2021 and opened each position for the duration of 1 Year:
0.00% of your transactions would have been profitable with an average return of -64.6%

Stock Rating Distribution

38Ratings
89.47% Buy
10.53% Hold
0.00% Sell
Distribution of Gobind Singh's ratings

Additional Information

Main Sector:General
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Protagonist Therapeutics Inc
(PTGX)
Rating Type:Buy
Dates:Dec 15, 2021 - Jan 01, 1970
Gain:0.00%
The most profitable rating made by Gobind Singh

Gobind Singh's Stock Coverage

Company Name
Date
Position
Action
Price Target
Success Rate
Avg Return
No. of Ratings
Evelo Biosciences
Nov 01, 2021
Buy
Reiterated
$41.50
(1414.60% Upside)
0%
-68.75%
9
Kaleido Biosciences
Nov 02, 2021
Buy
Reiterated
$22.00
(999900.00% Upside)
0%
-91.28%
5
Seres Therapeutics
Nov 23, 2021
Hold
Reiterated
$9.00
(67.60% Upside)
0.00%
4
Protagonist Therapeutics
Dec 15, 2021
Buy
Reiterated
$70.00
(514.04% Upside)
0%
-66.17%
13
Prothena
Jan 14, 2022
Buy
Reiterated
$77.00
(139.20% Upside)
0%
-31.80%
2
Immunic
Jan 18, 2022
Buy
Reiterated
$58.00
(1004.76% Upside)
0%
-44.10%
5
List of latest recommendations made by Gobind Singh. Click to expand and see Gobind Singh's performance on a particular stock
Disclaimer: TipRanks collects ratings and price targets of analysts by scanning publicly available reports on financial websites and by receiving reports directly from the analysts or from our users. The information displayed and the Analyst Profile statistics might not be accurate, complete, or up to date. The analyst ratings provided are entirely at the sole responsibility of the of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings or opinions expressed on the site.
Are We Missing a Rating?
Send us the equity research you are getting and become a Power User
Learn More